Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

1.56USD
22 Sep 2017
Change (% chg)

$0.03 (+1.96%)
Prev Close
$1.53
Open
$1.55
Day's High
$1.56
Day's Low
$1.52
Volume
27,571
Avg. Vol
141,515
52-wk High
$18.06
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $13.03
Shares Outstanding(Mil.): 8.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Celsion Corp Q2 loss per share $0.79

* Celsion corporation reports second quarter 2017 financial results and provides business update

Aug 15 2017

BRIEF-Celsion Corp says DMC completes mid-study review of phase III thermodox optima study

* Data monitoring committee completes mid-study review of Celsion's phase III thermodox optima study in primary liver cancer

Aug 07 2017

BRIEF-Celsion Corporation to delist from Tel Aviv stock exchange

* Celsion Corporation to delist from Tel Aviv stock exchange Source text for Eikon: Further company coverage:

Aug 04 2017

BRIEF-Celsion Corp announces data from ovation study

* Celsion corp - ‍announces latest translational data from ovation study in newly diagnosed advanced ovarian cancer patients​ Source text for Eikon: Further company coverage:

Aug 02 2017

BRIEF-Celsion Corp says Anson Funds Management LP reported 9.6 pct passive stake in Co as of July 6 - SEC filing

* Anson Funds Management LP reports 9.6 percent passive stake in Celsion Corp as of July 6 - SEC filing Source text: (http://bit.ly/2uBZEHu) Further company coverage:

Jul 17 2017

BRIEF-Intracoastal Capital reports 8.3 pct passive stake in Celsion

* Intracoastal Capital Llc reports 8.3 percent passive stake in Celsion Corp as of July 6 - SEC filing Source: (http://bit.ly/2vlTnMo) Further company coverage:

Jul 14 2017

BRIEF-Celsion Corp agreed to sell about 2.435 million shares of common stock

* Celsion Corporation announces $5 million registered direct offering

Jul 06 2017

BRIEF-Celsion announces completion of ovation study

* Celsion announces completion of ovation study and provides update on its immunotherapy trial in advanced stage III and IV ovarian cancer

Jul 05 2017

BRIEF-Celsion cancels registered direct offering

* Celsion Corporation announces cancellation of registered direct offering

Jun 22 2017

BRIEF-Celsion announces $5.4 million registered direct offering

* Celsion corporation announces $5.4 million registered direct offering

Jun 19 2017

Earnings vs. Estimates